中国医药指南
中國醫藥指南
중국의약지남
CHINA MEDICINE GUIDE
2013年
20期
432-432,433
,共2页
唐东红%陈秋华%武应祥%李晓磊
唐東紅%陳鞦華%武應祥%李曉磊
당동홍%진추화%무응상%리효뢰
奥扎格雷钠%低分子肝素钙%川穹嗪%糖皮质激素
奧扎格雷鈉%低分子肝素鈣%川穹嗪%糖皮質激素
오찰격뢰납%저분자간소개%천궁진%당피질격소
Sodium ozagrel%Low molecular heparin calcium%Ligustrazine%Glucocorticoid
目的探讨联合用药在治疗慢性阻塞性肺疾病急性加重中的作用。方法随机将住院的240例慢性阻塞性肺疾病患者分成对照组和观察组。对照组:采用常规治疗。观察组:在常规治疗的基础上加用奥扎格雷钠或低分子肝素钙联合川穹嗪、糖皮质激素治疗。结果经加用奥扎格雷钠或低分子肝素钙联合川穹嗪、糖皮质激素治疗后,患者的咳痰喘症状好转率与对照组相似,但提高了患者的生活质量并延长了患者再次入院的时间,而且未出现皮肤、黏膜出血现象。结论奥扎格雷钠或低分子肝素钙联合川穹嗪、糖皮质激素可作为治疗慢性阻塞性肺疾病常规用药。
目的探討聯閤用藥在治療慢性阻塞性肺疾病急性加重中的作用。方法隨機將住院的240例慢性阻塞性肺疾病患者分成對照組和觀察組。對照組:採用常規治療。觀察組:在常規治療的基礎上加用奧扎格雷鈉或低分子肝素鈣聯閤川穹嗪、糖皮質激素治療。結果經加用奧扎格雷鈉或低分子肝素鈣聯閤川穹嗪、糖皮質激素治療後,患者的咳痰喘癥狀好轉率與對照組相似,但提高瞭患者的生活質量併延長瞭患者再次入院的時間,而且未齣現皮膚、黏膜齣血現象。結論奧扎格雷鈉或低分子肝素鈣聯閤川穹嗪、糖皮質激素可作為治療慢性阻塞性肺疾病常規用藥。
목적탐토연합용약재치료만성조새성폐질병급성가중중적작용。방법수궤장주원적240례만성조새성폐질병환자분성대조조화관찰조。대조조:채용상규치료。관찰조:재상규치료적기출상가용오찰격뢰납혹저분자간소개연합천궁진、당피질격소치료。결과경가용오찰격뢰납혹저분자간소개연합천궁진、당피질격소치료후,환자적해담천증상호전솔여대조조상사,단제고료환자적생활질량병연장료환자재차입원적시간,이차미출현피부、점막출혈현상。결론오찰격뢰납혹저분자간소개연합천궁진、당피질격소가작위치료만성조새성폐질병상규용약。
Objective Discussion on the effect of combined drug therapy for acute exacerbations of chronic obstructive pulmonary diseases(COPD). Methods 240 in-patients with COPD were randomLy divided into 2 groups,an observation group(OG) and a control group(CG). The patients in the CG received conventional therapy,and besides the conventional therapy,sodium ozagrel or low molecular heparin calcium combined with ligustrazine and glucocorticoid were added to the therapy of patients in the OG. Results As for expectoration or asthma symptoms, the improvement rates were similar between the two groups. But after the therapy of adding sodium ozagrel or low molecular heparin calcium combined with ligustrazine and glucocorticoid, the patients in OG got much more improvement for quality of life and the readmission time interval was also extended, and did not appear the skin, mucous membrane bleeding. Conclusion Sodium ozagrel or low molecular heparin calcium combined with ligustrazine and glucocorticoid could be used as conventional drugs in the therapy of acute exacerbations of COPD.